<DOC>
	<DOCNO>NCT01383720</DOCNO>
	<brief_summary>This prospective , single-arm feasibility study design ass acute safety performance Lotus Valve System transcatheter aortic valve replacement symptomatic patient calcify aortic valve stenosis high risk surgical intervention .</brief_summary>
	<brief_title>REpositionable Percutaneous Replacement Stenotic Aortic Valve Through Implantation Lotus™ Valve SystEm</brief_title>
	<detailed_description>The incidence aortic stenosis increase due age world-wide population lack drug therapy prevent , halt , effectively slow stenotic process . Transcatheter aortic valve replacement become viable alternative treatment severe symptomatic aortic stenosis select patient unsuitable candidate surgical valve replacement . The Lotus Valve System design enable precise placement minimize eliminate paravalvular regurgitation associate adverse event see early generation device . The REPRISE I study ass acute safety performance .</detailed_description>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Patient must least 70 year age old , meet criteria . 2 . Patient document calcified native aortic valve stenosis , define initial aortic valve area &lt; 1.0 cm2 ( AVA index &lt; 0.6 cm2/m2 ) , mean pressure gradient &gt; 40 mmHg jet velocity &gt; 4 m/s , measure echocardiography . 3 . The patient consider high risk surgical aortic valve replacement STS score ≥8 % EuroSCORE ≥20 % , document multidisciplinary heart team agreement patient high risk surgery due frailty and/or coexist comorbidities . 4 . Symptomatic aortic valve stenosis NYHA Functional Class ≥ II . 5 . Patient document aortic annulus size 19 22 mm ( able accommodate 23 mm Lotus™ Valve ) . Preprocedure measurement transthoracic echocardiography ( TTE ) require . Other image modality ( e.g. , transesophageal echocardiography ( TEE ) , CT scan ) use adjunctive manner . 6 . Patient ( legal representative ) understand trial requirement treatment procedure , provide write informed consent . 7 . Patient agree capable return study hospital require schedule follow visit . 1 . Patient congenital unicuspid bicuspid aortic valve . 2 . Patient acute myocardial infarction within 30 day index procedure ( define Q wave MI , nonQ wave MI total CK elevation ≥ twice normal presence CKMB elevation and/or troponin level elevation ( WHO definition ) ) . 3 . Patient cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within past 6 month , permanent neurologic defect prior study enrollment . 4 . Patient dialysis serum creatinine level &gt; 3.0 mg/dL . 5 . Patient preexist prosthetic heart valve ( aortic mitral ) prosthetic ring position . 6 . Patient &gt; 2+ mitral regurgitation &gt; 2+ aortic regurgitation ( ie. , patient moderate mitral aortic regurgitation ) . 7 . Moderate severe pulmonary hypertension ( PA systolic pressure &gt; 60 mm Hg ) assess transthoracic echocardiography . 8 . Patient need emergency surgery reason . 9 . Patient history endocarditis within 12 month index procedure evidence active systemic infection sepsis . 10 . Patient echocardiographic evidence intracardiac mass , thrombus vegetation . 11 . Patient Hgb &lt; 9 g/dL , platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , white blood cell ( WBC ) count &lt; 3,000 cells/mm3 . 12 . Patient receive chronic ( ≥72 hour ) anticoagulation therapy ( e.g. , heparin , warfarin ) tolerate concomitant therapy aspirin clopidogrel ( patient require chronic anticoagulation must treat either aspirin clopidogrel ) . 13 . Patient active peptic ulcer disease , gastrointestinal ( GI ) bleed within past 3 month , bleed diathesis coagulopathy refuse transfusion . 14 . Patient contraindicate transesophageal echocardiography ( TEE ) . 15 . Patient known hypersensitivity contrast agent adequately premedicated , know hypersensitivity aspirin , thienopyridines , heparin , nickel , titanium , polyurethane . 16 . Patient life expectancy le 12 month due noncardiac , comorbid condition base assessment investigator time enrollment . 17 . Patient cardiac device hardware study device interfere device placement ( per physician judgment ) . 18 . Patient hypertrophic obstructive cardiomyopathy . 19 . Patient therapeutic invasive cardiac procedure within 30 day prior index procedure . 20 . Untreated clinically significant coronary artery disease require revascularization . 21 . Patient document LVEF &lt; 30 % . 22 . Patient cardiogenic shock hemodynamic instability require inotropic support mechanical support device . 23 . Patient severe peripheral vascular disease ( include aneurysm define maximal luminal diameter &gt; 5cm document presence thrombus , mark tortuosity , narrow abdominal aorta , severe unfold thoracic aorta thick ( &gt; 5mm ) , protrude ulcerated atheroma aortic arch ) symptomatic carotid vertebral disease . 24 . Patient femoral artery lumen &lt; 6.0 mm severe iliofemoral tortuosity calcification would prevent safe placement introducer sheath . 25 . Current problem substance abuse ( e.g . alcohol , cocaine , heroin , etc ) . 26 . Patient participate another investigational drug device study reach primary endpoint . 27 . Patient preexisting untreated conduction system disorder : Type II seconddegree AV block , bifascicular trifascicular block .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Aortic Valve Stenosis</keyword>
	<keyword>Transcatheter Aortic Valve Replacement</keyword>
</DOC>